Aspartyl protease inhibitors

US7868000B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Zhaoning Zhu · Plainsboro, US
• Brian McKittrick · New Vernon, US
• Andrew Stamford · Madison, US
• William J. Greenlee · Teaneck, US
• Xiaoxiang Liu · River Vale, US
• Mihirbaran Mandal · Scotch Plains, US
• Johannes H. Voigt · Cranford, US
• Corey Strickland · Bound Brook, US

Key dates

• Filing date: Jun 12, 2006
• Grant date: Jan 11, 2011
• Expiry date: Jun 12, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of the formula Ior a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein j, k, U, W, R, R1, R2, R3, R4, R6, R7 and R7a are as described above in the specification.Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.